Clinical Data – Talk Bio

Viking Therapeutics to Highlight VK2735 Clinical Data at ObesityWeek 2025

4 weeks ago talkbio0Tagged Clinical Data, Clinical Trials, GLP-1/GIP Dual Agonist, Metabolic Syndrome X, Obesity, ObesityWeek 2025, Prediabetes syndrome, VANQUISH-1, venture, Viking Therapeutics, VK2735

Viking Therapeutics; VK2735; ObesityWeek 2025; VENTURE trial; VANQUISH-1 trial; GLP-1/GIP dual agonist; clinical data; obesity; prediabetes; metabolic syndrome

CHMP Rejects Sanofi’s Rezurock Over Clinical Data Issues, Recommends Approval of BTK Inhibitor Wayrilz

1 month ago talkbio0Tagged Autoimmune thrombocytopenia, belumosudil, cGVHD, CHMP, chronic graft-versus-host disease, Clinical Data, Inosine Triphosphate, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, regulatory approval, Rezurock, Rilzabrutinib, sanofi, Wayrilz

Sanofi; CHMP; EMA; Rezurock; Wayrilz; Belumosudil; Rilzabrutinib; chronic graft-versus-host disease; cGVHD; immune thrombocytopenia; ITP; regulatory approval; clinical data

FDA’s Move to Update GSK’s Leucovorin for Autism Raises Questions on Dose, Supply, and Data

2 months ago talkbio0Tagged Autistic Disorder, Clinical Data, Dosage, drug relabeling, leucovorin, Neurodegeneration Due To Cerebral Folate Transport Deficiency, SmithKline Beecham, United States Food and Drug Administration, Wellcovorin

FDA; GSK; leucovorin; Wellcovorin; autism; cerebral folate deficiency; drug relabeling; dose; supply; clinical data

AstraZeneca Expands AI Collaboration with SOPHiA GENETICS for Breast Cancer Research

4 months ago talkbio0Tagged AI Factories, AstraZeneca, Clinical Data, Genomics, Malignant neoplasm of breast, predictive models, real-world evidence, SOPHiA GENETICS

AstraZeneca; SOPHiA GENETICS; AI Factories; breast cancer; predictive models; real-world evidence; genomics; clinical data

FDA Rejects Capricor’s Cell Therapy for Duchenne Muscular Dystrophy

5 months ago talkbio0Tagged Capricor Therapeutics, Cardiomyopathies, Cell Therapy, Clinical Data, Complete, deramiocel, HOPE-3 trial, Muscular Dystrophy, Duchenne, Phase 3, Rejection, Response process, United States Food and Drug Administration

FDA rejection; Capricor Therapeutics; deramiocel; Duchenne muscular dystrophy; DMD; cell therapy; cardiomyopathy; clinical data; Phase 3 HOPE-3 trial; Complete Response Letter

Invivyd Highlights Follow-Up to Pemgarda mAb Could Rival COVID Vaccines

5 months ago talkbio0Tagged Clinical Data, COVID19 (disease), immune compromise, Invivyd, long-acting protection, Monoclonal Antibodies, Pemgarda, vaccine alternatives

Invivyd; Pemgarda; VYD2311; monoclonal antibody; COVID-19; vaccine alternatives; immune compromise; long-acting protection; phase 1/2 clinical data

Lilly Posts Encouraging Early-Stage Weight Loss Data on Amylin Candidate

5 months ago talkbio0Tagged Amylin Candidate, aspects of adverse effects, Clinical Data, early-stage trial, Eli, Eli Lilly, Eloralintide, Obesity, Weight Loss

Eli Lilly; eloralintide; amylin candidate; weight loss; early-stage trial; obesity drug; clinical data; side effects

GLP-1s May Lower Cancer Risk; Gyre Stock Drops After Hep B Data, Share Offering

6 months ago talkbio0Tagged agonists, Cancer Risk, Clinical Data, GLP-1 receptor, Gyre stock, Hepatitis B, Mortality Vital Statistics, Obesity-Related Cancers

GLP-1 receptor agonists; cancer risk; obesity-related cancers; Gyre stock; hepatitis B; clinical data; mortality

Cytokinetics’ Phase III Trials Show Promise in Challenging Cardiomyopathy Treatment Dominated by BMS

2 years ago talkbio0Tagged BMS, Cardiomyopathies, Cardiovascular Diseases, Clinical Data, Cytokinetics, Heart failure, mecarbil, Myocardium, myosin inhibitors, omecamtiv, Phase 3 Clinical Trials

Cytokinetics, Phase III trials, cardiomyopathy, Bristol-Myers Squibb (BMS), heart failure treatment, myosin inhibitors, omecamtiv mecarbil, clinical data, heart muscle contraction, cardiovascular disease.

Cytokinetics Unveils Aficamten Data, Gears Up for Market Competition Against Camzyos

2 years ago talkbio0Tagged Aficamten, Camzyos, Cardiovascular Diseases, Clinical Data, commercial strategy, competition, Cytokinetics, Heart failure, Market, Myotonic Dystrophy

Cytokinetics, Aficamten, Camzyos, clinical data, cardiovascular disease, myotonic dystrophy, heart failure, commercial strategy, market competition.